Enjoy complimentary customisation on priority with our Enterprise License!
The peptide therapeutics market size is forecast to increase by USD 17.85 billion, at a CAGR of 10.03% between 2023 and 2028. The market landscape is shaped by several influential factors: the rising prevalence of infectious diseases, favorable reimbursement policies, and the development of drugs with extended half-lives. These elements collectively drive market dynamics by addressing critical healthcare needs, ensuring cost-effective treatment options, and enhancing therapeutic efficacy through prolonged drug action. The increasing incidence of infectious diseases underscores the urgent demand for innovative treatments and preventive measures. Concurrently, favorable reimbursement policies facilitate broader access to advanced therapies, supporting market expansion and patient affordability. Moreover, the advent of drugs with extended half-lives represents a significant advancement in pharmaceutical research, offering prolonged therapeutic effects and potentially improving patient adherence to treatment regimens. This intersection of infectious disease prevalence, reimbursement policies, and therapeutic innovation underscores a transformative phase in healthcare markets, characterized by enhanced treatment outcomes and improved patient care pathways. The report provides market size, historical data spanning from 2018 - 2022, and future projections, all presented in terms of value in USD billion for each of the mentioned segments.
For More Highlights About this Report, Request Free Sample
Peptide therapeutics represent a significant advancement in the biomedical industry, offering potential solutions for various chronic diseases, including cancer, metabolic disorders such as diabetes and obesity, osteoarthritis, and osteoporosis. Peptide-based therapeutic vaccines, hormonal therapy, and smoking cessation are among the applications under exploration. Novel drugs, including peptide-based and biologics, are being investigated for their clinical benefits in disease management. Small molecule-based interventions and pharmacological interventions complement peptide-based drugs in addressing disease conditions. Target specificity and low toxicity are essential advantages of peptide therapeutics, making them attractive alternatives to conventional treatments. Pediatric patients also stand to benefit from these innovative therapies. The peptide therapeutics market is witnessing continuous growth due to the increasing demand for effective treatments for chronic diseases. Novel leads and ongoing clinical investigations further fuel the market's expansion. In summary, peptide therapeutics offer promising prospects for addressing various health conditions with improved efficacy and safety.
The increasing prevalence of infectious diseases is notably driving market growth. The peptide therapeutics market has witnessed significant growth, driven by numerous FDA approvals for peptide-drug conjugates and innovative segment offerings. In the cancer segment, peptide-drug conjugates have shown promising clinical benefits due to their target specificity and low toxicity. The biotech sector has been a key contributor to this market, with pharmacological interventions and biologics leading the way. Peptide-based drugs have emerged as novel leads in drug development, particularly in the treatment of cardiovascular disorders and respiratory diseases. The hybrid technology segment has gained traction due to its ability to combine the advantages of both peptide and small molecule-based interventions.
Further, the pipeline molecules in this market offer dosing frequency advantages, making them attractive to Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) for clinical investigation. Cell penetrating peptides and drug delivery methods are also being explored to enhance the therapeutic potential of peptide drugs. Despite the challenges, the future of peptide therapeutics looks promising, with ongoing research and development efforts focused on improving target specificity, reducing toxicity, and increasing API stability. Thus, such factors are driving the growth of the market during the forecast period.
Collaborations for R&D is the key trend in the market. The peptide therapeutics market has experienced a significant expansion due to an increase in FDA approvals for peptide-based drugs. This growth can be attributed to the cancer segment, which dominates the market, with innovative peptide-drug conjugates and cell penetrating peptides leading the way. In the biotech sector, drug developers are focusing on in-house manufacturing and outsourcing manufacturing segments for peptide therapy products. Peptide-based drugs offer clinical benefits such as target specificity, low toxicity, and high target affinity. These advantages have led to the development of novel leads and the clinical investigation of peptide therapy products. Big pharma players are also investing in this area, with a focus on orphan drug designation and clinical studies for target disease indications.
Moreover, API stability and toxicity profiles are critical factors in the development of peptide-based drugs. CROs and CMOs are playing a crucial role in conducting clinical studies and ensuring the regulatory compliance of these products. The pipeline molecules in the peptide therapeutics market are expected to continue to grow, with a focus on novel targets and drug delivery methods. Thus, such trends will shape the growth of the market during the forecast period.
Complexities in manufacturing, storage conditions, distribution policies, and high cost is the major challenge that affects the growth of the market. The peptide therapeutics market encompasses the development, production, and commercialization of peptide-based drugs for various therapeutic indications. FDA approvals play a crucial role in bringing these innovative treatments to the market. In the cancer segment, peptide-drug conjugates (PDCs) have gained significant attention due to their ability to selectively target cancer cells, offering clinical benefits through improved target specificity and reduced toxicity. The market is segmented into the innovative segment, which focuses on developing novel peptide therapy products, and the generic segment, which deals with the production of peptide drugs with proven efficacy. In-house manufacturing and outsourcing manufacturing segments cater to the production requirements of drug developers.
Additionally, big pharma players and emerging biotech companies are investing in clinical studies to explore the potential of peptide therapy products for various target disease indications. Pipeline molecules in the peptide therapeutics market include peptide drug conjugates, cell penetrating peptides, and drug delivery methods that enhance the efficacy and safety of these treatments. CROs and CMOs play a vital role in supporting the clinical investigation and manufacturing processes for these novel therapeutics. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Amgen Inc. - The company offers Therapeutic proteins which are extensively used for the treatment of cancer, HIV, and other diseases.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The parenteral segment is estimated to witness significant growth during the forecast period. Peptide therapeutics have gained significant attention in the healthcare industry due to their potential in treating various chronic diseases, including cancer, metabolic disorders, hormonal therapy for diabetes and obesity, osteoarthritis, and osteoporosis. The oral delivery of peptide-based therapeutics remains a challenge due to their instability and degradation in the gastrointestinal tract. Consequently, the parenteral route, which involves administering drugs through injectable routes, has emerged as the most popular route of administration for peptide therapeutics.
Get a glance at the market share of various regions Download the PDF Sample
The parenteral segment accounted for USD 9.50 billion in 2018. Further, the market for peptide therapeutics is expected to grow significantly due to the increasing prevalence of chronic diseases and the development of novel drugs for their treatment. In the field of oncology, peptide therapeutics have shown potential in treating infectious diseases. The development of peptide therapeutics for infectious diseases is a growing area of research, with a focus on overcoming insolubility issues and improving stability. The use of peptide therapeutics in disease management is expected to expand, offering new treatment options for patients.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Peptide Therapeutics Market encompasses the development, production, and application of peptide-based drugs for various therapeutic areas. Oral peptide delivery systems have gained significant attention due to their potential to improve patient compliance and convenience. Peptide-based therapeutic vaccines hold promise in cancer treatment, as they can stimulate the immune system to target and destroy cancer cells. Peptide therapeutics are also being explored for metabolic disorders such as diabetes and obesity. Hormonal therapy, a common approach for managing metabolic diseases, relies on peptide hormones like insulin and GLP-1.
Additionally, creative Peptides and other companies are investing in research and development to address insolubility issues and improve the manufacturing process. Expensive manufacturing equipment and recombinant peptides are used to produce high-quality peptide therapeutics. Clinical trials are ongoing to evaluate the safety and efficacy of these drugs in various therapeutic areas, including oncology and infectious diseases. In conclusion, the Peptide Therapeutics Market is a rapidly growing industry that holds promise in the treatment of various chronic diseases, including cancer, metabolic disorders, and hormonal therapy. Oral peptide delivery systems, peptide-based therapeutic vaccines, and novel drugs are driving the market forward, with ongoing research and development addressing manufacturing challenges and expanding the therapeutic applications of peptide therapeutics.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
You may also interested in below market reports:
Obsessive-Compulsive Disorder (OCD) Drugs Market Obsessive-Compulsive Disorder (OCD) Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, France, China, Japan - Size and Forecast
Osteoarthritis Therapeutics Market Osteoarthritis Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Japan, Germany, China - Size and Forecast
Anti-obesity Drugs Market Anti-obesity Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, Canada, China - Size and Forecast
The market is a significant sector in the healthcare industry, driven by the discovery and development of novel peptide-based drugs. These therapeutics are derived from natural proteins and play a crucial role in treating various diseases and conditions. The market is characterized by the presence of numerous players engaged in research and development, production, and distribution of peptide therapeutics. Peptide therapeutics offer several advantages over small molecule drugs, including high specificity, low toxicity, and the ability to mimic the action of natural proteins. The market is segmented based on application areas, including cardiovascular diseases, neurological disorders, and oncology, among others. The market is expected to grow due to the increasing prevalence of chronic diseases and the rising demand for targeted therapies. Additionally, advancements in peptide synthesis technology and the development of new delivery systems are expected to drive market growth. The market is also influenced by regulatory frameworks and government policies, which impact the approval and commercialization of new peptide therapeutics. Furthermore, collaborations and partnerships between industry players and academic institutions are expected to accelerate the development of new peptide therapeutics. In conclusion, the Peptide Therapeutics market is a dynamic and evolving sector, driven by the growing demand for targeted therapies and the ongoing research and development efforts in this field. The market is expected to witness significant growth in the coming years, with numerous opportunities for players engaged in the production, distribution, and commercialization of these therapeutics.
Market Scope |
|
Report Coverage |
Details |
Page number |
148 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
Market growth 2024-2028 |
USD 17.85 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
8.88 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 45% |
Key countries |
US, Germany, China, UK, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Almac Group Ltd., AmbioPharm Inc., Amgen Inc., AstraZeneca Plc, Bachem AG, Bristol Myers Squibb Co., Corden Pharma International GmbH, Eli Lilly and Co., Ever Pharma, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Ipsen Pharma, Lonza Group Ltd., Novartis AG, Novo Nordisk AS, PeptiDream Inc., Pfizer Inc., PolyPeptide Group, Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Worg pharma |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.